Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC
Public ClinicalTrials.gov record NCT05595460. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1b Single Arm, Open-label Trial of RYZ101 in Combination With Carboplatin + Etoposide + Atezolizumab in Subjects With Somatostatin Receptor Expressing (SSTR+) Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Study identification
- NCT ID
- NCT05595460
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- RayzeBio, Inc.
- Industry
- Enrollment
- 21 participants
Conditions and interventions
Conditions
Interventions
- Atezolizumab Drug
- Carboplatin Drug
- Etoposide Drug
- RYZ101 Dose Level -1 Drug
- RYZ101 Dose Level 2 Drug
- RYZ101 Dose Level 3 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 9, 2022
- Primary completion
- Jun 30, 2027
- Completion
- Jun 30, 2027
- Last update posted
- Apr 12, 2026
2022 – 2027
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Facility | Los Angeles | California | 90024 | — |
| Research Facility | San Francisco | California | 94158 | — |
| Research Facility | Jacksonville | Florida | 32224 | — |
| Research Facility | Miami | Florida | 33136 | — |
| Research Facility | Orlando | Florida | 32806 | — |
| Research Facility | Iowa City | Iowa | 52242 | — |
| Reserach Facility | Lexington | Kentucky | 40536 | — |
| Research Facility | Grand Rapids | Michigan | 49503 | — |
| Research Facility | Rochester | Minnesota | 55905 | — |
| Research Facility | St Louis | Missouri | 63130 | — |
| Research Facility | Omaha | Nebraska | 68130 | — |
| Research Facility | Salt Lake City | Utah | 84112 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05595460, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 12, 2026 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05595460 live on ClinicalTrials.gov.